Evidence map›Paper›PMID 40887418›Full record

Trial reportZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Luspatercept combined with roxadustat in the treatment of refractory myelodysplastic neoplasms with ring sideroblasts: a prospective, randomized, single-center study].

X Y Lu, Z X Zhang, Z W Liu, C Yang, M Chen, B Han

Abstract readRandomized Controlled TrialEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

X Y LuDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
Z X ZhangDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
Z W LiuDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
C YangDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
M ChenDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
B HanDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.

Funding

Beijing Natural Science Foundation 7232109CAMS Innovation Fund for Medical Sciences 2023-12M-C&T-B-013National High Level Hospital Clinical Research Funding 2022-PUMCH-C-026, 2022-PUMCH-D-002, 2022-PUMCH-B-046National Natural Science Foundation of China 82370121
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Activin Receptors, Type IIGlycineImmunoglobulin Fc FragmentsIsoquinolinesMyelodysplastic SyndromesRecombinant Fusion ProteinsAdultAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeActivin Receptors, Type IIGlycineImmunoglobulin Fc FragmentsIsoquinolinesluspaterceptRecombinant Fusion ProteinsroxadustatErythroid responseLuspaterceptMyelodysplastic neoplasmsProspective randomized controlled trialRoxadustat

Identifiers

PMID40887418
PMCPMC12439732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.